由于在代谢位置用更稳定的C-D键代替C-H键可以增强药物的药代动力学,因此氘代药物(重药)作为小分子药物的新形式最近受到关注。因此,用于候选药物的氘代方法是药物化学中的热门话题。其中,H/D交换反应(将C-H键直接转化为C-D键)是创建新型氘代目标分子的有用且直接的方法,近年来发表了20多篇关于H/D交换反应相关合成方法的综述。尽管各种氘代候选药物都经过临床试验,已批准的氘代药物在同一分子中具有CD3基团。然而,更少的多样化,除了CD3组,是未来药物化学的问题.最近,我们使用D2O作为廉价的氘源,基于相应氢形式的H/D交换反应,开发了各种氘代烷基(dn-烷基)锍盐,将CD3,CH3CD2和ArCH2CD2基团引入候选药物。这一概念总结了最近有关H/D交换反应和引入CD3基团的新型试剂的综述。并讨论了我们新开发的亲电子dn-烷基试剂。
Deuterated drugs (heavy drugs) have recently been spotlighted as a new modality for small-molecule drugs because the pharmacokinetics of pharmaceutical drugs can be enhanced by replacing C-H bonds with more stable C-D bonds at metabolic positions. Therefore,
deuteration methods for drug candidates are a hot topic in medicinal chemistry. Among them, the H/D exchange reaction (direct transformation of C-H bonds to C-D bonds) is a useful and straightforward method for creating novel deuterated target molecules, and over 20 reviews on the synthetic methods related to H/D exchange reactions have been published in recent years. Although various deuterated drug candidates undergo clinical trials, approved deuterated drugs possess CD3 groups in the same molecule. However, less diversification, except for the CD3 group, is a problem for future medicinal chemistry. Recently, we developed various deuterated alkyl (dn-alkyl) sulfonium salts based on the H/D exchange reaction of the corresponding hydrogen form using D2O as an inexpensive deuterium source to introduce CD3, CH3CD2, and ArCH2CD2 groups into drug candidates. This concept summarises recent reviews related to H/D exchange reactions and novel reagents that introduce the CD3 group, and our newly developed electrophilic dn-alkyl reagents are discussed.